Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib in IDH1-mutated CCUS and Lower-risk MDS/CMML
NCT06566742Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and Objective Response Rate. Started Dec 2024; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
clonal cytopenia of undetermined significance (CCUS)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06566742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566742.